Skip to main content
SpringerLink
Log in

Capecitabin neoadjuvant bei Brustkrebs

  • Literatur kompakt_Mammakarzinom und gynäkologische Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Eine primäre Chemotherapie ist die Therapie der Wahl bei lokal fortgeschrittenem Mammakarzinom, vor allem wenn eine brusterhaltende Therapie nicht möglich ist. Kann zusätzliches Capecitabin die Ansprechraten steigern?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Steger GG et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: Final results of a randomized phase III study (ABCSG-24). Ann Oncol. 2014;25(2):366-71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. Capecitabin neoadjuvant bei Brustkrebs. Im Focus Onkologie 17, 26 (2014). https://doi.org/10.1007/s15015-014-1210-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1210-2

Search

Navigation